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Meeting Proceedings
Summary of the Fibromyalgia Research Symposium
2016 in Nagasaki
Daniel J. Clauwa, Hiroshi Uedab
aThe University of Michigan, Ann Arbor MI, USA
bDepartment of Pharmacology and Therapeutic Innovation,
Nagasaki University Graduate School of Biomedical Sciences,
Nagasaki, Japan
The IASP Satellite Symposium on Fibromyalgia (FM) took place
from October 1 to 2 in Nagasaki, Japan. The conference was co-
hosted by Dr. Hiroshi Ueda of Nagaskai University and Dr. Daniel
Clauw from the University of Michigan. The conference began
with opening remarks from Dr. Ueda and then the Keynote
address was delivered by Dr. Clauw. Dr. Clauw stated his opinion
that the pathophysiology of FM is fairly well understood and is
primarily due to central nervous system (CNS) dysfunction that
leads to multifocal pain, as well as fatigue accompanied by sleep,
memory, and mood difficulties. Dr. Clauwmade the case that the
CNS theory of FM is the only one that has moved past simply
showing an association between findings and the presence of FM
to showing that specific CNS abnormality (eg, abnormal levels of
neurotransmitters in the CNS) targeted by drugs with specific
mechanisms of action leading to improvement in the subset of
individuals with FMwho display that particular pathophysiological
abnormality. The following talk was by Dr. Winfried Hauser, who
emphasized the importance of psychosocial stressors in the
development and worsening of individuals with FM. Dr. Kathleen
Sluka presented both preclinical and clinical data, suggesting that
FM was characterized by diffuse hyperalgesia/allodynia and that
both the periphery and CNS may be contributing to symptoms
such as fatigue. Dr. Jon Levine presented mainly preclinical
studies, suggesting that both CNS and peripheral factors could
potentially be playing a role in FM. Dr. Hiroshi Ueda then
presented a series of preclinical studies using an intermittent cold
stress model in mice that leads to the development of diffuse
hyperalgesia and pain behaviors, reminiscent of those seen in
FM, and responds to the same types of CNS-acting drugs that
work in patients. Dr. Lars Arendt-Nielsen presented a series of
studies performed by his group and others showing that the
cardinal features of diffuse hyperalgesia/allodynia can be
identified in subsets of virtually every chronic pain condition. Dr.
Hiroshi Oka introduced the current status of FM treatment in
Japan. The first day ended with 2 speakers in oral presentation.
Dr. Chie Usui gave a talk about positron emission tomography
study in FM, and Dr. Deepak Sharan gave a talk about the 5-year
follow-up of individuals in a multidisciplinary FM treatment center
in India.
The following day began with Dr. Claudia Sommer’s pre-
sentation of her group’s and others data showing that patients
with FM have reduced intraepidermal nerve fiber density and
postulated that this is playing a role in the pathogenesis of FM. Dr.
Manuel Martinez-Lavin then presented his theory that FM is
a sympathetically mediated pain syndrome. Dr. Roland Staud
suggested that some of the CNS hyperalgesia in FM is reduced
when individuals are infused with lidocaine, such that peripheral
nociceptive input might be partly responsible for driving the
central sensitization seen in FM. Dr. Eva Kosek then followed by
presenting neuroimaging and quantitative sensory testing data,
suggesting that the CNS hyperactivity in FM can bemodulated by
both pharmacological and nonpharmacological therapies. Dr.
Richard Harris followed by showing evidence that the endoge-
nous opioid system may be partly responsible for the CNS
hyperactivity and symptoms seen in FM and suggested that this
may explain why opioid therapy is often either ineffective in FM or
sometimes actually leads to worsening of symptoms. The
following oral presentation was by Dr. Kenji Miki who showed
a phase IIa trial of mirtazapine which showed some evidence of
efficacy in FM, and then Dr. Kenichi Osada presented a new
device for detection of small fiber neuropathy. Abstracts of all
presentations whose authors expressed an interest in participat-
ing in this report are presented below.
In summary, this internationally recognized set of speakers
highlighted the fact that much is now known regarding the
potential pathogenic mechanisms in FM. Nearly all agree that
CNS factors play a predominant role in FM, but there are
emerging data suggesting that peripheral factors may also play
a role in some individuals and that these individuals might benefit
from a different treatment plan than thosewith pure CNS disease.
Overview of fibromyalgia clinical syndrome
[Keynote Lecture]
Daniel J. Clauw
The University of Michigan, Ann Arbor MI, USA
The thinking regarding fibromyalgia (FM) has changed
tremendously over the past 2 decades. Originally thought to be
a discrete disorder, it is now clear that it might be better
considered the end of a continuum, where the key clinical
features are multifocal pain accompanied by somatic syndromes
such as fatigue, sleep, and memory difficulties. Many but not all
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individuals with FM also have elevated levels of psychological
distress—but both clinical and mechanistic studies clearly
demonstrate that the key elements of fibromyalgia and psycho-
logical distress are independent of each other (but often
co-occur). This independence of FM from psychological factors
is especially true in individuals who have elevated high levels of
“fibromyalgianess” (FMness—or centralized pain) but do not
meet criteria for fibromyalgia. In these individuals with “sub-
threshold FM,” there is a linear relationship between FMness and
important clinical features (eg, nonresponsiveness to opioid
analgesics and surgery), and this linear relationship only
disappears when studies focus only on individuals at the end of
this continuum (ie, those who meet criteria for FM).
The neurobiology of FM and centralized pain is becoming
increasingly well understood, with abnormalities in levels of
central nervous system (CNS) neurotransmitters, increases in
pain and sensory responsiveness, and neuroimaging evidence of
changes in functional connectivity as well as the size and shape of
key brain structures. Nearly all of the treatments that are effective
for subsets of patients with FM are directed toward these CNS
abnormalities.
Fibromyalgia is now considered in the broader pain field to be
the model for centralized pain, wherein pain and other symptoms
are originating more so from the CNS than the periphery.
Individuals with centralized pain are less responsive to classic
and commonly used analgesic regimens (nonsteroidal anti-
inflammatory drugs, opioids, injections, and surgery). They re-
spond better to CNS-acting analgesics and aggressive use of
nonpharmacological therapies aimed at the CNS. In summary, FM
and centralized pain is “a different type of pain that requires an
entirely different type of treatment.”
[Lecture-1]
The importance of psychosocial factors in the etiology and
management of fibromyalgia
Winfried Ha¨user
Department of Psychosomatic Medicine and Psychotherapy,
Technische Universita¨t Mu¨nchen, Germany
A model of interacting biological and psychosocial variables in
the predisposition, triggering, and development of the chronicity
of fibromyalgia syndrome (FMS) has been suggested. One
prospective longitudinal population-based study demonstrated
the association of lifestyle factors (sleep disturbances, obesity
combined with low physical activity, and smoking) and the
development of FMS. Workplace bullying and depression
predicted the onset of FMS in one longitudinal cohort study
each. A systematic review of case–control studies demonstrated
an association of retrospective reports of childhood physical and
sexual abuse and diagnosis of FMS in adulthood. Traumatic and
major life events and long-term daily hassles might contribute—in
genetically predisposed individuals—to central sensitivity and
impaired descending pain inhibition.
The lifetime prevalence of mental disorders (anxiety, de-
pression, and posttraumatic stress disorder) is up to 80% in
patients with FMS. A systematic review of case series demon-
strated that depression has a negative impact on FMS outcome
(severity of symptoms and disability) and the success of
multicomponent treatment. Two case series demonstrated that
posttraumatic stress disorder has a negative impact on FMS
outcome and working status.
A network meta-analysis demonstrated that drugs and
cognitive behavioral therapies (CBTs) did not significantly differ
in their efficacy at the end of treatment. However, the positive
effects of drugs disappear after discontinuation within 2 weeks. In
contrast, CBTs have a sustained reduction of pain, disability, and
depression at 6-months follow-up (Cochrane review of random-
ized controlled trial). Finally, acceptance-basedCBTwas superior
to the best available drug therapy (duloxetine and/or pregabalin)
in improvement of quality of life at the end of treatment and at 6
months in a randomized controlled trial. Management of
moderate and severe forms of FMS which are mainly due to
mental comorbidities should include a mental health care
specialist.
[Lecture-2]
Mechanisms underlying the transition from acute to
chronic pain
Kathleen A. Sluka
The University of Iowa, Iowa, USA
The underlingmechanisms involved in the transition fromacute
to chronic pain are critically important for preventing and treating
chronic pain. Multiple stressors in a critical window may alter
central neuron excitability and local immune responses. Neuronal
plasticity in the nervous system and alterations in the local
immune systemby these stressorsmay underlie the development
of chronic widespread pain. Dr. Sluka will present ongoing
research examining the neurobiological mechanisms underlying
the development of chronic widespread pain. She will show data
examining sex differences and the protective role of testosterone,
altered immune system activation in themuscle, and alterations in
descending facilitation in animal models of chronic widespread
pain.
[Lecture-3]
Fibromyalgia: the nerve of that disease
Jon D. Levine
Department of Medicine and Division of Neuroscience,
University of California, San Francisco, USA
Fibromyalgia is a chronic widespread pain syndrome that
currently has no pathognomonic feature or biomarker that allows
diagnostic certainty and may present as a manifestation of
another condition (secondary fibromyalgia). Thus, development
of preclinical models provides a special opportunity to dissect
underlying mechanisms. Given the importance of stress in
fibromyalgia syndrome, we have focused on models of stress-
induced pain. The results of these studies will be presented and
the role of the neuroendocrine stress axis presented.
[Lecture-4]
Brain mechanisms and pharmacotherapy in generalized
chronic pain model similar to fibromyalgia in mice
Hiroshi Ueda
Department of Pharmacology and Therapeutic Innovation,
Nagasaki University Graduate School of Biomedical Sciences,
Nagasaki, Japan
We have established a novel mouse model of generalized
chronic pain model similar to fibromyalgia, using intermittent cold
stress (ICS) exposure. This model was found to show long-lasting
mechanical allodynia, thermal hyperalgesia, and other hyper-
sensitivities to chemical and electrical stimuli. Female-predominant
genderdifferencewasobservedonly after thegonadectomy. In this
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talk, I will introduce a series of pharmacological studies and discuss
underlying brain mechanisms and better pharmacotherapy. For
the ICS exposure,micewereplaced in a cold roomat 4˚C overnight
(from 4:30 PM to 10:00 AM), followed by ICS with alternating
environmental temperatures between 24 and 4˚C every 30 min
from 10:00 AM to 4:30 PM. These procedures were repeated twice.
On day 3 (P1), the mice were returned to and adapted to a room
temperature of 24˚C for 1 hour before the nociception tests. In the
ICS-induced generalized chronic pain model in mice, morphine
had no significant analgesic effects when given in a systemic or
intracerebroventricular (i.c.v.) route. Significantmorphine analgesia
was observed when NMDA receptor subunit, NR2A-deficient
mice, or an NR2A antagonist (i.c.v.) was treated. The repeated co-
administration of pregabalin with valspodar, an inhibitor of
P-glycoprotein (p-gp), showed complete relief of pain at least for
another week after the cessation of treatments. However, there
was no morphine analgesia even after the complete recovery from
chronic pain. The co-administration with the p-gp inhibitor also
showed a potent potentiation of antihyperalgesia by duloxetine
(intraperitoneal [i.p.]). In contrast, mirtazapine, another type of
antidepressant (NaSSA) showed potent antihyperalgesic effects
without the p-gp inhibitor, and repeated treatments showed
complete relief from pain memory. After the repeated treatments
with mirtazapine, morphine analgesic effects were recovered.
Repeated treatments with donepezil also showed a complete relief
from the chronic pain, butmorphine analgesia was not recovered. I
will discuss about brain mechanisms of all these pharmacother-
apeutic effects.
[Lecture-5]
Mechanistic similarities between fibromyalgia and other
chronic pain conditions
Lars Arendt-Nielsen
Center for Sensory-Motor Interaction, School of Medicine,
Aalborg University, Aalborg, Denmark
Peripheral and central sensitization are important mechanisms
for fibromyalgia (FM) and musculoskeletal pain conditions in
general. Many similarities exist between different chronic muscu-
loskeletal pain conditions. Musculoskeletal pain may transit from
a localized pain problem through a regional representation to
a widespread pain condition such as FM. As the pain condition
transit from one to the other,more andmore sensory abnormalities
occur with many sensory abnormalities in FM. There is evidence
that as well the intensity of ongoing pain as the duration of pain
determine thedegree of generalized hyperalgesia. This is important
to realize as it underpins the importance of the ongoing nociception
for the chronification process in conditions (eg, osteoarthrosis)
where the peripheral nociceptive drivers are known, whereas it is
more complicated in, eg, FM where the drivers are less obvious.
It is generally accepted that pain diagnosis and therapy should
be mechanism based, and hence, pain assessment tools (pain
biomarkers) should be sufficiently sensitive and advanced to
provide such mechanistic information. Translating clinical obser-
vations to mechanisms and vice versa are not trivial, and tools to
assess quantitatively the different phenomena are mandatory.
Such techniques for assessing the peripheral–central pain
sensitization mechanisms in patients with FM and other patients
with musculoskeletal pain have been developed and provide the
opportunity to quantify pain mechanisms such as temporal
summation, descending inhibition, spreading sensitization, and
additional modality-specific hyperalgesic reactions. Such tools
can help to phenotype patients with FM based on the role of the
various pain sensitizationmechanisms involved and have recently
been used as tools to predict pain outcomes after pharmaco-
logical or surgical interventions in various groups of musculo-
skeletal pain conditions.
Relating clinical benefit of a given therapy with quantitative
assessment of the pain sensitization mechanisms involved
provides new opportunities for better diagnostics and hence for
tailored and individualized management regimes.
Although assessed differently in specific tissues for various
musculoskeletal pain conditions, the underlying mechanisms
share common underlying features. This mechanistic under-
standing is of importance for developing better diagnostics and
for implementing tailored pain management programs. The
understanding that FM and other musculoskeletal conditions
share common fundamental features has positioned FM as the
one extreme end as opposed to, eg, amyofascial pain problem at
the other end. This has provided some new insight into the
development of the sensitization processes from one extreme to
the other.
[Lecture-6]
Fibromyalgia treatment in Japan
Hiroshi Oka
Tokyo Rheumatism Pain Clinic, Tokyo, Japan
We have 3 double-blind multicenter placebo-controlled
clinical trials for fibromyalgia (FM) in Japan. The first clinical trial
was pregabalin (P-3). This trial demonstrated that pregabalin, at
doses of up to 450 mg/d, was effective for the symptomatic
relief of pain in Japanese patients with FM. Pregabalin also
improved measures of sleep and functioning and was well
tolerated. These data indicate that pregabalin is an effective
treatment option for the relief of pain and sleep problems in
Japanese patients with FM.
The second clinical trial was duloxetine (P-3). Duloxetine
treatment was associated with improved outcomes in secondary
and post-hoc analyses of the mean change in the BPI average
pain score and most of the secondary outcomes, including
analgesia and QOL. Duloxetine treatment was safe and well
tolerated. These results suggest that duloxetine treatment could
be associated with improvements in pain relief and QOL in
Japanese patients with FM.
The third clinical trial was mirtazapine (P-2). Compared with
placebo, mirtazapine produced a significantly greater analgesic
effect and significantly greater improvements in QOL in terms of
job ability, anxiety, and role or social functioning. Of note,
mirtazapine was found to be effective in controlling FM pain even
in patients without coexisting depression; other treatments are
neurotropin, tramadol, and tramset in Japan.
[Lecture-7]
The role of peripheral nociceptors in fibromyalgia syndrome
Claudia Sommer
Department of Neurology, University of Wu¨rzburg, Germany
In recent years, data have accumulated showing pathoana-
tomical and functional abnormalities of peripheral nociceptors in
patients with fibromyalgia syndrome (FMS). Taking together the
cumulative data by several groups of researchers, this may be
true for approximately 50% of the patients classified as the
fibromyalgia group and may indicate an important subtype. In
particular, quantitative sensory testing has shown deficits in
thermal and tactile sensation in patients with FMS, indicating loss
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of function in A-delta and C-fibers or their afferent tracts. These
data from the psychophysical testing are supported by findings
from studies using evoked potentials like laser-evoked potentials
and so-called pain-related evoked potentials, which show
reduced amplitudes in patients with FMS.While these techniques
do not allow a differentiation between a lesion in peripheral or
central parts of the somatosensory system, skin biopsy and
microneurography findings have clarified this issue. Confirmed by
data from several laboratories, a subgroup of patients with FMS
has a reduced intraepidermal nerve fiber density, indicating
a peripheral pathology. This is supported by microneurography
findings, where patients with FMS, like those with painful small
fiber neuropathy, have increased spontaneous activity in
nociceptors. Furthermore, patients with FMS have abnormal
activity-induced slowing, which further differentiates them from
patients with classical small fiber neuropathy. A possible
explanation for this phenomenon is the finding that dermal
C-fibers in patients with FMS are thinner than those of controls.
A first potential explanation for the small fiber pathology of FMS
has come from research on micro RNAs. We recently showed
that miR-let-7d and its downstream target insulin-like growth
factor-1 (IGF-1R) are aberrantly expressed in skin of patients
with FMS with small nerve fiber impairment. Further research is
needed to evaluate the significance of these findings for the
pathophysiology of FMS.
[Lecture-8]
Fibromyalgia as a sympathetically maintained neuropathic
pain syndrome
Manuel Martinez-Lavin
Department of Rheumatology, National Institute of Cardiology,
Mexico
Our group has proposed that fibromyalgia is a neuropathic pain
syndrome based on the following 3 arguments: (1) fibromyalgia is
a stimulus-independent pain state; (2) the presence of allodynia as
an essential feature of fibromyalgia; and (3) the presence of
paresthesias as a distinctive feature of fibromyalgia. Among
neuropathic syndromes, we propose that fibromyalgia pain is
sympathetically maintained based on the following issues: the high
frequency of physical, infectious, or psychological stressors as
a triggering event; diverse heart rate variability studies showing that
patients with fibromyalgia have changes consistent with ongoing
sympathetic hyperactivity; a double-blind study demonstrating that
norepinephrine injections rekindle fibromyalgia pain; the associ-
ated variations of the COMT gene and the adrenergic receptor
gene, and finally, studies using the Composite Autonomic
Symptom Score (COMPASS) questionnaire showing that fibro-
myalgia patients have prominent dysautonomia symptoms.
The recent finding of small fiber neuropathy in most patients
with fibromyalgia reinforces the notion of fibromyalgia as
a sympathetically maintained neuropathic pain syndrome.
Corneal confocal microscopy has corroborated the presence of
small nerve fiber pathology in fibromyalgia.
The SCN9A-encoded dorsal root ganglia sodium channels’
(Nav1.7) genetic variations provide an additional link between
fibromyalgia and small fiber neuropathy. Severe fibromyalgia is
associated with the Nav1.7 rs6754031 GG genotype. However,
gain-of-function mutations in sodium channel Nav1.7 are present
in 28% of patients with small fiber neuropathy.
Outlook: Fibromyalgia is a sympathetically maintained neuro-
pathic pain syndrome. Autonomic dysfunction provides a co-
herent explanation for the multiple nonpain-related fibromyalgia
symptoms. Corneal confocal microscopy could become a useful
noninvasive fibromyalgia diagnostic procedure. Dorsal root
ganglia sodium channels are attractive therapeutic targets.
[Lecture-9]
Peripheral mechanisms of pain and fatigue in patients with
fibromyalgia or chronic fatigue
Roland Staud
Department of Medicine, Rheumatology and Clinical Immu-
nology, University of Florida, Gainesville, Florida, USA
Patients with musculoskeletal pain syndrome including fibro-
myalgia (FM) complain of chronic pain fromdeep tissues including
muscles as well as often disabling fatigue. Previous research
suggests the relevance of impulse input from deep tissues for
clinical FM pain. Similarly, activated metaboreceptors of muscles
seem to contribute to chronic fatigue.
We enrolled 62 female patients with FM and 58 patients with
chronic fatigue into 2 double-blind controlled studies to receive
200mg lidocaine or saline injections into the trapezius and gluteal
muscles. In addition to pain and fatigue, study variables included
pressure and heat hyperalgesia. Furthermore, all patients were
asked to indicate by forced choice after the injections whether
they had received the active study drug or normal saline.
Primary mechanical hyperalgesia at the shoulders and
buttocks of FM and chronic fatigue syndrome subjects de-
creased significantly more after lidocaine than saline injections
(P , 0.05). Similar results were obtained for secondary heat
hyperalgesia at the arms (P , 0.05). After muscle injections,
clinical FM pain and chronic fatigue significantly declined by 38%
and 35%, respectively. According to postinjection question-
naires, subjects could not reliably distinguish whether they had
received lidocaine or saline injections.
These results suggest that tissue injections can reliably reduce
clinical FM pain and chronic fatigue and that peripheral impulse
input is required for the maintenance of hyperalgesia and chronic
fatigue in patients with chronic musculoskeletal pain.
Acknowledgements: These studies were supported by an
NIH grant R01 NR014049-01 and NIH/NCATS Clinical and
Translational Science grants UL1 TR000064. None of the authors
have any financial or other relationships that might result in
a conflict of interest.
[Lecture-10]
The effects of treatment on central pain modulation—lessons
learned from functional magnetic resonance imaging studies
Eva Kosek
Department of Clinical Neuroscience and Osher Center,
Karolinska Institutet and Stockholm Spine Center, Stockholm,
Sweden
Fibromyalgia (FM) is associated with a generalized hypersensi-
tivity to painful stimuli, and behaviour data indicate a dysfunction of
descending pain inhibitory pathways. Therefore, central sensitiza-
tion has been proposed to be an important pathophysiological
mechanism in FM. The latter is supported by studies using
functionalmagnetic resonance imaging demonstrating augmented
nociceptive processing and reduced pain-related activation of
rostral anterior cingulate cortex and thalamus, ie, cerebral regions
implicated in pain modulation. These abnormalities were not
associated with the degree of rated depression or anxiety,
suggesting separate processing of negative affect and nociceptive
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input. In addition, patients with FM had less pain-related functional
connectivity within the brain’s pain inhibitory network and structural
changes such as decreased cortical thickness and reduced brain
volumes. There was an overlap between these functional and
structural abnormalities, and both were more pronounced in
patientswith a longer duration of FM, suggesting a time-dependent
progress of cerebral pathology in FM.
Furthermore, a short duration of FM predicted a better outcome
after a 12-week treatment with the serotonin–noradrenalin reup-
take inhibitor milnacipran. The degree of improvement and
reductions in pain sensitivity after the milnacipran treatment cor-
responded to increased pain-related activation of precuneus,
a cerebral area associated with pain modulation, and the default-
mode network. In contrast, 12 weeks of cognitive behaviour
therapy did not affect clinical pain or pain sensitivity but increased
activations of cerebral regions implicated in executive cognitive
control during painful stimulation and thus likely affected reap-
praisal of painful stimuli. Finally, a newly developed protocol of
individually graded physical exercise for 15 weeks reduced
symptoms and pain sensitivity. The elevated interstitial glutamate
and pyruvate concentrations in the quadriceps muscle of patients
with FM normalized after the exercise intervention. Pain-related
cerebral activation was not affected, indicating that peripheral
muscular mechanisms were involved in pain relief. However,
a partial normalization of cerebral resting-state activity and
improved cognitive functioning was seen in patients with FM after
the exercise intervention. In conclusion, we demonstrated that at
least some of the cerebral abnormalities in patients with FM are
reversible. The fact that different treatment modalities affected
specific cerebral mechanisms would support the rational for
combination therapies in FM.
[Lecture-11]
Neural basis of multimodal sensory augmentation
in fibromyalgia
Richard E. Harris
Department of Anesthesiology, University of Michigan, Ann
Arbor MI, USA
Pain can be elicited throughout all mammalian sensory pathways,
yet cross-modal sensory integration, and its relationship to pain in
clinical conditions, has largely been unexplored. Fibromyalgia is the
prototypical centralized chronic pain condition that is characterized
by symptoms of multimodal sensory hypersensitivity, wherein
individuals have aversive responses to touch/thermal stimuli, loud
sounds, and even bright lights. As such, it is thought that this
condition involves a large-scale amplification of sensory processes
that cut across multiple modalities. Previous work suggests that the
locus for this sensory integration may lie within the insular cortex as
this structure has consistently displayed altered neurochemical
imbalances aswell as aberrant functional connectivity that have both
been associated with the magnitude of clinical pain in this
population. Here, I will present data demonstrating cross-modal
sensory hypersensitivity to visual as well as pressure stimuli in
patients with fibromyalgia and also investigate how changes in this
activity can be modulated with pregabalin, a compound showing
efficacy in this population. We will explore how functional magnetic
resonance imaging has revealed that insular activity evoked by
simple visual stimulation is intimately associated with chronic pain
in fibromyalgia. Moreover, attenuation of this insular activity by the
analgesic pregabalin is accompaniedby concomitant reductions in
clinical pain. These dynamic processes during pregabalin treat-
ment occur in concert with reductions in insular glutamate (the
brain’smajor excitatory neurotransmitter), graymatter volume, and
functional connectivity between the default mode network
(a constellation of brain regions activated during rest and self-
referential thinking). Finally, I will also present data frommultivariate
classification methods using support vector machines applied to
visual-evoked brain activity that can distinguish patients with
fibromyalgia from healthy controls with significant accuracy.
Interestingly, a separate support vector machine classification of
treatment effects on visual-evoked activity canalso identify patients
administered with pregabalin as compared with placebo: impor-
tantly regions differentiating patients from controls and pregabalin
from placebo treatment share overlapping insular topology. These
data strongly suggest that abnormal integration of multisensory
pathways within the insula may represent a pathophysiological
mechanism in centralized chronic pain. Furthermore, insular
response to aversive visual stimulation may also have utility as
a marker for analgesic drug development beyond pregabalin, in
particular for compounds that target the central nervous system.
This work is supported by grants from Pfizer Inc, the Dana
Foundation, Department of Defense (Army Grant: DAMD-
W81XWH-07-2-0050), and National Institutes of Health (NCCIH:
P01 AT006663, R01-AT007550).
[Oral-1]
A study of brain metabolism in fibromyalgia by positron
emission tomography
Chie Usui
Department of Psychiatry, Juntendo University Nerima Hospi-
tal, Japan
Purpose: The aim of this study was to determine the brain
regions with altered metabolism in patients with treatment-naive
fibromyalgia (FM).
Methods:We studied a total of 18 drug-naive patients with FM
and 18 healthy controls without suffering from pain and who were
matched for age and sex. [18F] fluoro-D-glucose positron emission
tomography was tested in both patients with FM and controls. A
voxel-by-voxel group analysis was performed using SPM8.
Results: No significant voxel (peak)-level result was detected in
this study; however, some regions were detected as significant-
size clusters. There was no significant difference in brain
metabolism between patients with FM and controls. However,
the right thalamus and left lentiform nucleus were hypermetabolic
areas in patients with FM with poor prognosis compared with the
healthy controls. In contrast, the left insula and left lentiformnucleus
were hypometabolic areas in patientswith FMwith good prognosis
compared with the healthy controls. Compared with patients with
FMwith good prognosis, FM patients with poor prognosis showed
significant hypermetabolism in the left thalamus, bilateral lentiform
nucleus, and right parahippocampal gyrus.
Conclusion: These findings suggest anassociationbetween the
metabolism in the thalamus, lentiform nucleus, and parahippocam-
pal gyrus and a prognosis in patients with FM. Further study with
larger number of patients is required to confirm this finding.
This research is supported by the chronic pain research project
from the Japan Agency for Medical Research and development,
AMED.
[Oral-2]
Outcome of a sequenced multidisciplinary rehabilitation
protocol for fibromyalgia—5-year follow-up
Deepak Sharan
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RECOUP Neuromusculoskeletal Rehabilitation Centre,
Bangalore, India
A study was conducted in 2009 to assess the outcome of
a sequenced multidisciplinary rehabilitation for fibromyalgia
syndrome (FMS) in 30 subjects (18 males and 12 females) at
a follow-up of 1 year. A 5-year follow-up study was performed in
the same individuals. All the subjects were diagnosed by an
experienced orthopedic and rehabilitation physician and were
treated with a sequenced multidisciplinary rehabilitation protocol.
The outcomes measured included pain and sleep with visual
analog scale, fatigue using Borg CR 10 scale, and depression
with help of Beck Depression Inventory, Fibromyalgia Impact
Questionnaire, and Short Form-36. Of the samples, 26 were
software professionals, 3 were housewives, and 1was a teacher.
Nineteen subjects (12 males and 7 females) participated in the
5-year follow-up study. Eleven subjects had changed their contact
details and could not be contacted. Mean scores during the first
visit, at 1-year, and 5-year follow-ups were 6.56, 2.1, and 1.2 for
pain, 5.36, 1.53, and 1 for fatigue, 5.7, 1.56, and 1 for
sleeplessness, and 10.6, 4.7, and 2.64 for Beck Depression
Inventory, respectively. Results of paired t test showed a significant
difference (P. 0.05) between Fibromyalgia Impact Questionnaire
and Short Form-36 scores of the first visit, 1-year, and 5-year
follow-ups. Significant improvement (P . 0.05) in pain reduction,
sleep, and fatigue was noticed after the 5-year follow-up. The
subjects were not taking any specific treatment for FMS other than
home-based exercises at the time of the last follow-up. This study
emphasizes the need for a comprehensive sequenced multidisci-
plinary approach for effective treatment of FMS. There was
a significant improvement in pain, sleep, fatigue, depression, and
general quality of life, and the effects were maintained at a follow-
up of 5 years.
[Oral-3]
Efficacy of mirtazapine for the treatment of fibromyalgia
without concomitant depression: a randomized double-
blind placebo-controlled phase IIa study in Japan
Kenji Mikia, Masato Murakamib, Hiroshi Okac, KanameOnozawad,
Sadahiro Yoshidad, Kenichi Osadae
aDepartment of Pain Medicine, Osaka University Graduate
School ofMedicine,Center for painmanagement,Hayaishi Hospital
bSanno Hospital, International University of Health andWelfare
cDepartment of Rheumatology, Hachioji Medical Center,
Tokyo Medical University
dClinical Research Planning Department, Meiji Seika Pharma
Co, Ltd
eDepartment of Neuropsychiatry, St. Marianna University
School of Medicine, Japan
To evaluate the efficacy and safety of mirtazapine in Japanese
patients with fibromyalgia (FM), a parallel-group randomized
double-blind placebo-controlled phase IIa study was conducted
at 57 sites. Patients aged 20 to 64 years who met the American
College of Rheumatology 1990 diagnostic FM criteria and had
stably high pain scores during a placebo run-in period were
randomly assigned to receivemirtazapine (15mg/d for 1 week and
then 30 mg/d) or matching placebo for 12 weeks. The primary
endpoint was change in mean numerical rating scale pain score
from baseline to endpoint (week 12 or early discontinuation). Of
430 patients randomized (n5 215 each group), 422 (n5 211 each
group) were analyzed for the primary endpoint. At the endpoint,
mirtazapine caused a significantly greater reduction of mean
numerical rating scale pain score compared with placebo
(difference 0.44; 95% confidence interval, 20.72 to 20.17; P 5
0.0018). The reduction bymirtazapine remained greater compared
with placebo from week 6 onward. Mirtazapine also improved
pain-related quality of life assessed by the Japanese version of the
Fibromyalgia Impact Questionnaire and the Short Form-36
questionnaire. Adverse events were more common with mirtaza-
pine than placebo (68.8% vs 56.7%), including somnolence
(32.1% vs 7.4%), weight gain (17.7% vs 0.9%), and increased
appetite (11.6% vs 3.3%). In conclusion, mirtazapine was an
effective and safe treatment for Japanese patients with FM.
[Oral-4]
The investigation to the offset phenomenon for fibromyalgia
to detect the pain with the medical instrument X
Kenichi Osadaa, Yoshifuji Matsumotob, Hirohiko Kuratunec,
Syunpei Yokotad, Chie Usuie, Kenya NIshiokaf, Masako Kikuchig,
Kusuki Nishiokah
aDepartment of Neuropsychiatry, St. Marianna University
School of Medicine
bDepartment of Rheumatology, Kuwana City Medical Center
cDepartment of Welfare & Health Science, Kansai Univ.
Welfare Sciences
dDeartment of Pediatric Intractable Disease, Tokyo Medical
Univ. Institute of Medical Science
eDepartment of Psychiatry, Juntendo Univ. Nerima Hospital
fDepartment of Neurology, Juntendo Univ. Hospital
gDepartment of Pediatrics, Yokohama City Univ. Medical
Center
hTokyo Medical University, Institute of Medical Science, Japan
Offset analgesia responses were in a population of patients
with neuropathic pain with small fiber neuropathy (Anesthesiol-
ogy, M. Niesters, 2011;115:1063). We investigate the offset
analgesia responses for the 119 patients with fibromyalgia by the
pain detected with medical instrument X (detected small fiber
neuropathy).This study was a prospective cohort study in multi-
institutional joint research. Offset analgesia responses were
measured by medical instrument X (Q-sense; Medoc).
Offset analgesia was diapered to patients with fibromyalgia, as
the same as the patients with neuropathic pain. After offset, the
pain of fibromyalgia was correlated with the total J-FIQ score (P,
0.001; r5 0.343). The peak value to the pain of the patients with
depression (n 5 5) was decreased compared with that of the
controls (n 5 17).
We considered that these data demonstrated that patients
with fibromyalgia had the offset analgesia for the first time in the
world. We considered that fibromyalgia might be included to the
probable neuropathic pain syndrome.
[Poster-1]
Study on fibromyalgia patients with urinary complaints
Yuki Sekiguchi, Ayako Nakamura
Women’sClinic LUNAGroup, LUNAPelvic Floor Total Support
Clinic, Department of Female Urology, Yokohama city, Japan
Introduction: Fibromyalgia is the disease that leads to various
somatic complaints in addition to pain of the whole body. This
time, patients with fibromyalgia with lower urinary tract com-
plaints were studied.
Patients and Methods: Retrospectively, we reviewed the
number of patients with fibromyalgia from January to March 2016
in the LUNA Pelvic Floor Total Support Clinic. Next, the patients
with fibromyalgia were reviewed with or without urinary tract
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complaints. If patients had urinary tract complaints, they were
checked for diagnosis by the urology department. In addition, the
rates of efficacy of treatment were compared in the fibromyalgia
group with and without urinary tract complaints. Regarding the
diagnosis of fibromyalgia were used ACR1990, and the treatment
efficiency was decided with the visual analog scale scale. We
judged “effective treatment” if visual analog scale points de-
creased more than 2.
Results: There were 82 cases including first and revisits during
3 months in the LUNA Pelvic Floor Total Support Clinic. Twenty-
nine (35%) patients had lower urinary tract complaints, of which
there were 16 (65%) bladder pain syndrome or interstitial bladder
cases, 8 (27%) nonneurogenic overactive bladder cases, 2 (7%)
neurogenic overactive bladder cases.
The efficacy rate of treatment with and without lower urinary
tract complaints was 83% and 62%, respectively. The patients
with fibromyalgia with lower urinary tract complaints were relieved
of pain easier than those without lower urinary tract complaints,
but their lower urinary tract complaints got worse alternatively
after pain relief.
Conclusion: Patients with fibromyalgia with lower urinary tract
complaints could get pain control easier than those without lower
urinary tract complaints, but their lower urinary tract complaints
remain after pain relief.
[Poster-2]
Progressive brain changes in patients with chronic fatigue
syndrome: confirmation of a longitudinal magnetic
resonance imaging study by a larger cross-sectional study
Z. Y. Shana, Richard Kwiatekb, R. Burnetc, P. Del Fanted, D. R.
Stainesa, S. M. Marshall-Gradisnika, L. R. Barndena
aNational Centre for Neuroimmunology and Emerging
Diseases, Griffith University, Southport, QLD
bModbury Hospital, Adelaide, SA
cRoyal Adelaide Hospital, Adelaide, SA
dHealthfirst Network, Adelaide, SA, Australia
Acceptance of fibromyalgia as a debilitating multidimensional
medical disorder has been hampered by limited longitudinal
research and lack of evidence of structural pathology. The chronic
fatigue syndrome (CFS) is a disorder with considerable overlap of
clinical features with fibromyalgia (Psychol Med 2002;32:881–8).
The aim of this study was to uniquely assess for progressive
regional and total brain volume changes in CFS. Twenty-five
Canadian Consensus Criteria defined patients with CFS, and 25
matched healthy controls (HCs) had 3D gradient-echo brain
magnetic resonance imaging scans performed (T1). Six years later,
15 CFS and 10 HCs of original study had repeat scans (T2).
Twenty-five new CFS and 4 new HCs were recruited for an
independent cross-sectional study (T3). Magnetic resonance
imaging scans were interrogated using optimised (J Magn, Res
Imaging 2016; DOI:10.1002/jmri.25283), whole-brain, SPM12
voxel-based morphometry (VBM). Cross-sectional between-
group grey matter and white matter (WM) VBM analysis of T1,
T2, and T3 revealed no significant differences. Voxel-based
morphometry comparison of rates of change in WM volume
between T2 and T1 for the 15 CFS and 10 HCs in T2 revealed
a significant regional 4.5% reduction over 6 years in the posterior
left inferior fronto-occipital fasciculus (corrected cluster PFWE 5
0.03, MNI co-ordinates 245, 220, 220). Cross-sectional
between-group VBM of T2 plus T3 (40 CFS vs 14 HC) revealed
significantly reduced regional WM volume in the left inferior fronto-
occipital fasciculus in CFS (corrected cluster PFWE 5 0.005, MNI
co-ordinates 252, 212, 216). For the first time, in any functional
somatic syndrome, in any organ system, we have demonstrated
progressive structural pathology, confirmed by a larger
cross-sectional study. At the very least, these data indicate
that patients with CFS experience a chronic organic brain
syndrome. Notably, there exist no published reports of temporal
lobe WM volume loss in depression, anxiety, or stress.
Supported by the Judith Jane Mason Foundation.
[Poster-3]
Nonclassical antidepressant mirtazapine shows long-lasting
relief of generalized chronic pain and recovers morphine
analgesia in an experimental fibromyalgia-like intermittent
cold stress–model mice
Hiroshi Ueda, Takehiro Mukae, Hiroyuki Neyama, and Wakako
Fujita
Department of Pharmacology and Therapeutic Innovation,
Nagasaki University Graduate School of Biomedical Sciences,
Japan
We have established a novel mouse model of generalized
chronic pain model similar to fibromyalgia (FM), using intermittent
cold stress (ICS) exposure. This model was found to show long-
lasting mechanical allodynia, thermal hyperalgesia, and other
hypersensitivities to chemical and electrical stimuli. Female-
predominant gender difference was observed only after the
gonadectomy. In a series of studies, we obtained the therapeutic
effects of gabapentinoids and classical antidepressants, but not
morphine in the ICS model. All these findings suggest the
consistency to the clinical evidence for FM. In this study, we focus
the beneficial effects of various types of antidepressants in terms
of the site of action and therapeutic potentials. For the ICS
exposure, mice were placed in a cold room at 4˚C overnight (from
4:30 PM to 10:00 AM), followed by ICS with alternating
environmental temperatures between 24 and 4˚C every 30 min
from 10:00 AM to 4:30 PM. These procedures were repeated
twice. On day 3 (P1), the mice were returned to and adapted to
a room temperature of 24˚C for 1 hour before the nociception
tests. Duloxetine and milnacipran showed potent antihyperalge-
sic effects when given intrathecally (i.t.) but not systemically (i.p.)
or i.c.v. at P5. Mirtazapine, a nonclassical receptor antagonist-
type antidepressant showed potent antihyperalgesic effects by
i.p. injection. Its potent antihyperalgesic effects were also
observed by i.c.v. injection but not i.t. injection. Repeated i.p.
injections of mirtazapine from P5 to P11 caused the complete
relief of abnormal pain even at P19, 7 days after the cessation of
treatments. In addition, these treatments also recovered the
morphine analgesic effects. All these findings suggest that
repeated mirtazapine treatments cure the abnormal pain disease
or pain memory in a FM-like animal model.
[Poster-4]
Beneficial effects by co-administration of pregabalin or
duloxetine with P-glycoprotein inhibitor in intermittent cold
stress–induced fibromyalgia-like model in mice
Takehiro Mukae, Hiroyuki Neyama, Yuki Morishita, Soichiro
Kawamoto, Chiho Miyama, Ryoko Tsukahara, Hiroshi Ueda
Department of Pharmacology and Therapeutic Innovation,
Nagasaki University Graduate School of Biomedical Sciences,
Japan
We are looking for better pharmacotherapeutic treatments for
generalized chronic pain disease by use of our established
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intermittent cold stress (ICS) model in mice. In a series of studies,
we have demonstrated that the ICS model has many features
similar to fibromyalgia in terms of pathophysiological (generalized
chronic pain with female-predominant gender difference) and
pharmacotherapeutic aspects (sensitive to gabapentinoids and
antidepressants but not morphine). In the ICS exposure, mice
were placed in a cold room at 4˚C overnight (from4:30 PM to 10:00
AM), followed by ICS with alternating environmental temperatures
between 24 and 4˚C every 30 min from 10:00 AM to 4:30 PM.
These procedures were repeated twice. On day 3 (P1), the mice
were returned to and adapted to a room temperature of 24˚C for 1
hour before the nociception tests. In this study, we focused the
beneficial potentials of P-glycoprotein (P-gp) inhibitors for the
antihyperalgesic effects of pregabalin and duloxetine. Pregabalin
(i.p.) showed potent antihyperalgesic effects in the ICS model.
The combined treatment with valspodar, a P-gp inhibitor,
decreased effective doses and prolonged the duration of
pregabalin (i.p.)-induced antihyperalgesic effects. The repeated
combined daily treatments of pregabalin and valspodar from P5
to P11 completely cured the basal hyperalgesic threshold 7 days
after the cessation of drug treatments. Duloxetine showed potent
antihyperalgesic effects when given i.t. but not i.p. The
combination of duloxetine (i.p.) with tariquidal, another type of
P-gp inhibitor, showed potent antihyperalgesic effects, and
repeated treatments also cured the basal hyperalgesic threshold
7 days after the cessation of drug treatments. We are pursuing
the mechanistic clarification of the P-gp–induced potentiation in
terms of neurochemical and pharmacokinetic aspects.
[Poster-5]
Pathophysiological and pharmacotherapeutical actions in
intermittent cold stress– and acidic saline–induced
fibromyalgia/myalgia-like models in mice
Hiroyuki Neyama, Takehiro Mukae, Wakako Fujita, Hiroshi Ueda
Department of Pharmacology and Therapeutic Innovation,
Nagasaki University Graduate School of Biomedical Sciences, Japan
We have established a novel mouse model of generalized
chronic pain model similar to fibromyalgia (FM), using intermittent
cold stress (ICS) exposure. This model was found to show long-
lasting mechanical allodynia, thermal hyperalgesia, and other
hypersensitivities to chemical and electrical stimuli. Female-
predominant gender difference was observed only after the
gonadectomy. In this presentation, we compared the pharma-
cological features in ICS model and intramuscular acidic saline
model. Particularly in this presentation, we focus the therapeutic
effects of donepezil and morphine. For the ICS exposure, mice
were placed in a cold roomat 4˚C overnight (from4:30 PM to 10:00
AM), followed by ICS with alternating environmental temperatures
between 24 and 4˚C every 30 minute from 10:00 AM to 4:30 PM.
These procedures were repeated twice. On day 3 (P1), the mice
were returned to and adapted to a room temperature of 24˚C for 1
hour before the nociception tests (Nishiyori and Ueda, Mol Pain
2008;4:52). For the acidic saline model, it was as reported
previously by Sluka et al. (Sluka et al. Muscle Nerve 2001;24:
37–46). Intermittent cold stress model showed abnormal pain
behaviors in thermal hyperalgesia, mechanical allodynia, and
hypersensitivities to electrical, chemical (formalin i.p. or acetic
acid i.p.), and muscle pain stimulation, respectively. Acidic saline
model showed mechanical allodynia but not thermal hyper-
algesia. To compare the pharmacological effects in both ICS and
acidic saline models, mechanical paw withdrawal tests were
performed at P5 when they were given i.p. or subcutaneously,
respectively. Donepezil showed potent antiallodynic effects in the
mechanical pawwithdrawal tests in a dose range of 0.001 to 0.01
mg/kg (i.p.) at P5 in the ICS model. When donepezil was treated
at P5, P7, and P9, the hyperalgesia was completely gone at P12
and P18. In the acidic saline model, however, donepezil shows
muchweaker effect with themedian effective dose (ED50);1mg/
kg (i.p.) at P5. On the contrary, morphine (s.c., i.c.v., and i.t.) did
not show any antiallodynic effect in the ICS model, whereas it
showed significant beneficial effects with 1 mg/kg s.c., 0.1 nmol
i.c.v., and 1 nmol i.t., respectively in the acidic saline model.
Pregabalin (i.p.) showed significant allodynic effects in both
models. These results suggest that ICS model has more
generalized pain symptoms and closer pharmacotherapeutic
features to the clinical evidence in terms of lack of morphine
analgesia than acidic saline model. To propose that donepezil is
a new candidate for the treatment of FM, further basic and clinical
information should be obtained.
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